Core Viewpoint - The stock of Jibeier has experienced a decline recently despite a year-to-date increase, indicating potential volatility in its market performance [2]. Group 1: Stock Performance - As of November 19, Jibeier's stock price decreased by 2.00%, trading at 29.33 CNY per share with a total market capitalization of 5.849 billion CNY [1]. - Year-to-date, Jibeier's stock has risen by 34.05%, but it has seen a decline of 5.99% over the last five trading days, 8.00% over the last 20 days, and 21.28% over the last 60 days [2]. Group 2: Company Overview - Jibeier Pharmaceutical Co., Ltd. was established on November 13, 2001, and went public on May 18, 2020. The company specializes in the research, production, and sales of pharmaceuticals [2]. - The main revenue sources for Jibeier include Likujun tablets (72.72%), Nigulol tablets (14.20%), Yipingfeng capsules (4.88%), and others [2]. Group 3: Financial Performance - For the period from January to September 2025, Jibeier reported a revenue of 704 million CNY, reflecting a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase year-on-year [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million CNY in dividends, with 252 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, Jibeier had 7,742 shareholders, an increase of 28.97% from the previous period, with an average of 25,759 circulating shares per shareholder, a decrease of 22.46% [2]. - Notable new institutional shareholders include Caitong Advantage Industry Rotation Mixed Fund and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3].

Core Viewpoint - The company, Jibeier (688566), is focusing on expanding its market presence and product sales, particularly in underdeveloped regions, while also advancing its new drug development efforts, including an antidepressant and an oncology drug. Sales Strategy and Market Development - The company acknowledges significant sales disparities across regions and is implementing strategies to enhance sales in underperforming areas, aiming for regions like South and Central China to reach 80% of East China's sales levels [2] - The company has established a dedicated division and expert network to promote its hypertension drug, Niqunluo Tablets, which has shown strong sales growth, with over 7,000 hospitals covered as of September 2025, and an increase of 2,500 hospitals in the past year [2][11] Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 704 million yuan, a year-on-year increase of 9.52%, and a net profit of 197 million yuan, up 12.8% [16] - In Q3 2025, the company achieved a single-quarter revenue of 249.5 million yuan, a 19.08% increase year-on-year, driven by sales growth in its core products [10][16] New Drug Development - The company is preparing to submit the application for its antidepressant drug JJH201501, which has completed Phase III clinical trials and demonstrated efficacy comparable to existing treatments [6][14] - The oncology drug JJH201601 is currently in Phase IIa trials, focusing on cholangiocarcinoma patients, with plans for further clinical trials in advanced head and neck cancers [9] Future Development Strategy - The company plans to leverage its product and technological advantages to expand the sales scale of key products like Likujun Tablets and Niqunluo Tablets, while also accelerating new drug development [7] - The company aims to enhance communication with the secondary market to improve its stock performance, despite recent underperformance [5]

Core Viewpoint - The company is actively preparing the application materials for the new drug JJH201501 and is progressing with the subsequent processes while ensuring compliance with information disclosure obligations [1] Group 1 - The company is responding to investor inquiries regarding the status of the new drug application [1] - The company will disclose relevant information in accordance with regulations through designated media [1]

Core Viewpoint - The company is strategically investing in stem cell technology through equity stakes in two firms, focusing on innovation and future application potential [2] Group 1: Investment Strategy - The company has invested in Zhejiang Shengchuang Precision Medical Technology Co., Ltd. and Shanghai Aisaar Biotechnology Co., Ltd., both related to stem cell technology [2] - The investment decision will consider factors such as product innovation, technological advancement, and future application prospects [2] - The company emphasizes a cautious approach in selecting investment projects based on its development needs [2]

Core Viewpoint - The company is developing a stem cell injection (SC01009) for various diseases, including idiopathic pulmonary fibrosis, hepatitis B-related decompensated cirrhosis, and mild to moderate acute respiratory distress syndrome, with a focus on idiopathic pulmonary fibrosis currently undergoing Phase II clinical trials [1] Group 1 - The company has a stake in Zhejiang Shengchuang Precision Medical Technology Co., Ltd., which is working on the stem cell injection [1] - The indications for the stem cell injection include idiopathic pulmonary fibrosis, hepatitis B-related decompensated cirrhosis, and mild to moderate acute respiratory distress syndrome [1] - The Phase II clinical trial for idiopathic pulmonary fibrosis is currently in progress [1]

Group 1 - The company is currently preparing the necessary materials for the new drug application of JJH201501 as per relevant requirements [1]

Core Viewpoint - The stock of Jibeier has experienced a decline of 2.02% on November 10, with a current price of 31.01 CNY per share, despite a year-to-date increase of 41.73% [1] Financial Performance - For the period from January to September 2025, Jibeier achieved a revenue of 704 million CNY, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase compared to the previous year [2] - Cumulative cash dividends since the A-share listing amount to 476 million CNY, with 252 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Jibeier is 7,742, an increase of 28.97% from the previous period, while the average circulating shares per person decreased by 22.46% to 25,759 shares [2] - The top ten circulating shareholders include new entrants such as Caitong Advantage Industry Rotation Mixed A and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3] Stock Market Activity - On November 10, Jibeier's trading volume reached 40.387 million CNY, with a turnover rate of 0.65% and a total market capitalization of 6.184 billion CNY [1] - The stock has seen a decline of 9.17% over the last five trading days, 6.60% over the last twenty days, and 1.30% over the last sixty days [1] Business Overview - Jibeier, established on November 13, 2001, and listed on May 18, 2020, is primarily engaged in the research, production, and sales of pharmaceuticals [1] - The main revenue sources include Likujun tablets (72.72%), Niqurol tablets (14.20%), Yupingfeng capsules (4.88%), and other products [1]

Core Viewpoint - The company Gibeal's new antidepressant drug JJH201501 has completed Phase III clinical trials, showing significant efficacy and safety advantages over existing treatments, particularly the commonly used drug Vortioxetine, addressing the unmet needs of approximately 95 million depression patients in China [1][4]. Group 1: Clinical Data and Efficacy - JJH201501 demonstrates superior efficacy compared to placebo and comparable efficacy to Vortioxetine at a lower dosage, with 10mg and 15mg doses showing significant improvement after 8 weeks of treatment [2][3]. - The drug's mechanism, based on deuterated drug development technology, allows for lower doses to achieve higher efficacy, enhancing patient exposure and prolonging the drug's half-life [2][3]. Group 2: Safety Profile - JJH201501 exhibits a competitive safety profile, with adverse reaction rates leading to permanent discontinuation being comparable to placebo and significantly lower than Vortioxetine, particularly regarding gastrointestinal side effects [2][3]. - Improved safety is expected to enhance medication adherence among patients requiring long-term treatment for depression [2][3]. Group 3: Market Potential - The global antidepressant market is substantial, with over 350 million patients worldwide and 95 million in China, indicating a significant unmet demand for effective treatments [4][5]. - JJH201501 is positioned to become a first-line treatment option in the antidepressant market, potentially driving growth for Gibeal if successfully approved and included in insurance coverage [4][6]. Group 4: Competitive Landscape - The current antidepressant market in China is dominated by imported original drugs and domestic generics, with a lack of innovative local products, positioning JJH201501 as a much-needed addition [4][5]. - The drug's expected long-term usage cycle, similar to that of Vortioxetine, supports its potential for sustained market growth [3][4].

Core Points - The company will hold an online investor briefing on November 14, 2025, from 15:00 to 16:00 to discuss its Q3 2025 performance and financial indicators [2][3][4] - Investors can submit questions in advance until November 13, 2025, at 16:00, and the company will address common concerns during the interactive session [2][4] - Key personnel attending the meeting include the Chairman, General Manager, CFO, Board Secretary, and an Independent Director [5] Meeting Details - The meeting will be conducted via text interaction on the Dongfang Caifu Roadshow platform [4][6] - Contact information for inquiries includes the Securities Investment Department, with a phone number and email provided [6] Additional Information - After the meeting, investors can access the main content and details of the briefing on the Dongfang Caifu Roadshow platform [6][7]

证券代码：688566 证券简称：吉贝尔 公告编号：2025-049 江苏吉贝尔药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2025 年 11 月 14 日（星期五）15:00-16:00 会议召开方式：线上文字互动 投资者可于 2025 年 11 月 13 日（星期四）16:00 前通过邮件、电话等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 江苏吉贝尔药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）发布《公司 2025 年第三季度报 告》，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财 务状况、发展理念，公司计划于 2025 年 11 月 14 日（星期五）15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本 ...